Brief: Tango Therapeutics Announces Presentation Of Preclinical Data On Prmt5 Inhibitors Tng908 And Tng462 In Three Abstracts Accepted At 34Th Eortc-Nci-Aacr Symposium On Molecular Targets And Cancer Therapeutics
19/10/2022 12:19
Oct 19 (Reuters) - Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS ANNOUNCES PRESENTATION OF PRECLINICAL
DATA ON
PRMT5 INHIBITORS TNG908 AND TNG462 IN THREE ABSTRACTS ACCEPTED
AT 34TH EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER
THERAPEUTICS
Source text for Eikon: ID:nGNX3vjBdh
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,